ABSTRACT
Background: Over the past 15 years, comparative assessments of psychoactive substance harms to both users and others have been compiled by addiction experts. None of these rankings however have included synthetic cannabinoids or non-opioid prescription analgesics (NOAs, e.g., gabapentinoids) despite evidence of increasing recreational use. We present here an updated assessment by German addiction medicine experts, considering changing Western consumption trends-including those of NOAs. Methods: In an initial survey, 101 German addiction medicine physicians evaluated both physical and psychosocial harms (in 5 dimensions) of 33 psychoactive substances including opioids and NOAs, to both users and others. In a second survey, 36 addiction medicine physicians estimated the relative weight of each health and social harm dimension to determine the overall harm rank of an individual substance. We compared our ranking with the most recent European assessment from 2014. Results: Illicit drugs such as methamphetamine, heroin, cocaine and also alcohol were judged particularly harmful, and new psychoactive drugs (cathinones, synthetic cannabinoids) were ranked among the most harmful substances. Cannabis was ranked in the midrange, on par with benzodiazepines and ketamine-somewhat more favorable compared to the last European survey. Prescribed drugs including opioids (in contrast to the USA, Canada, and Australia) were judged less harmful. NOAs were at the bottom end of the ranking. Conclusion: In Germany, alcohol and illicit drugs (including new psychoactive substances) continue to rank among the most harmful addictive substances in contrast to prescribed agents including opioid analgesics and NOAs. Current laws are incongruent with these harm rankings. This study is the first of its kind to include comparative harm rankings of several novel abused substances, both licit/prescribed and illicit.
ABSTRACT
Impulsiveness has been linked to fast guesses and premature responses in reaction time tasks like the Eriksen flanker task or the Go/Nogo task. In the present study, healthy subjects without history of DSM-IV Axis I or II psychopathology were examined. Impulsiveness was determined by calculating individual reaction times (as a function of general response speed) in order to split the entire group (n = 26) in a subgroup with a more controlled response style (low impulsiveness [LI] group; n = 13) and a subgroup with a more impulsive response style (high impulsiveness [HI] group; n = 13). Subjects performed a Go/Nogo task while a multi-channel EEG was recorded. Two event-related potentials (ERP) were of special interest: the Nogo-N2 and -P3 component. HI subjects had significantly reduced (less positive) Nogo-P3 amplitudes compared to LI subjects whereas groups did not differ with regard to the Nogo-N2. These results corroborate previous findings of reduced Nogo-P3 amplitudes in samples with enhanced levels of impulsiveness. Moreover, present data suggest that there is a broader range of impulsiveness even in healthy subjects which might mask or pronounce between-group differences in clinical studies. Therefore, different levels of impulsiveness in control groups should be carefully taken into account in further ERP studies.
Subject(s)
Cerebral Cortex/physiology , Decision Making/physiology , Evoked Potentials/physiology , Impulsive Behavior/physiopathology , Judgment/physiology , Reaction Time/physiology , Adolescent , Adult , Electroencephalography , Female , Humans , Impulsive Behavior/diagnosis , Male , Mental Processes/physiology , Neural Inhibition/physiology , Neuropsychological Tests , Observer Variation , Reference Values , Time FactorsABSTRACT
Major depressive disorder (MDD) can be characterized by a wide-ranging profile of cognitive deficits including attention, memory, and executive functions which is possibly due to reduced volumes and a hypometabolism of the anterior cingulate cortex, orbitofrontal, and dorsolateral prefrontal cortex. We examined 21 patients with MDD in partial remission and 21 age-, sex-, and education matched healthy controls using event-related potentials (ERPs). Participants performed a hybrid flanker Go/Nogo task while multichannel EEG was recorded. Two ERP components were of interest which repeatedly have been linked to response inhibition: the Nogo-N2 and the Nogo-P3 which can be observed in Nogo trials of a Go/Nogo task. MDD patients showed a specifically reduced Nogo-P3 while the Nogo-N2 and the P3b in Go trials were unaffected. These results provide further evidence of impaired response monitoring and control processes in patients with MDD.
Subject(s)
Decision Making/physiology , Depressive Disorder, Major/physiopathology , Depressive Disorder, Major/psychology , Evoked Potentials/physiology , Inhibition, Psychological , Neuropsychological Tests , Adult , Brain Mapping , Case-Control Studies , Electroencephalography/methods , Female , Humans , Male , Middle Aged , Multivariate AnalysisABSTRACT
Depression in former ecstasy users may not respond to selective serotonin reuptake inhibitors (SSRIs) possibly due to damaged serotonergic synapses following long-term heavy ecstasy use. We report findings in a patient suffering from MDMA-induced depression which was refractory to several antidepressive medications including selective noradrenergic reuptake inhibitor (SNRI) and SSRI. An add-on repeated bilateral electroconvulsive therapy (ECT) was able to achieve a stable remission of affective and cognitive symptoms with a follow-up of more than 1.5 years. Add-on ECT could be a treatment option in former ecstasy users with severe depressive disorders that fail to respond to SSRI and/or SNRI. Clinical trials are needed to evaluate further the usefulness of ECT in this patient group.
